Medulloblastoma

被引:80
作者
Bartlett, F. [1 ]
Kortmann, R. [2 ]
Saran, F. [3 ]
机构
[1] Royal Marsden NHS Fdn Trust, Dept Radiotherapy, Sutton SM2 5PT, Surrey, England
[2] Univ Klinikum Leipzig, Dept Radiotherapy & Radiooncol, Leipzig, Germany
[3] Royal Marsden NHS Fdn Trust, Dept Neurooncol & Paediat Oncol, Sutton SM2 5PT, Surrey, England
关键词
Chemotherapy; clinical trials; medulloblastoma; paediatrics; radiotherapy; PROSPECTIVE RANDOMIZED-TRIAL; PRIMITIVE NEUROECTODERMAL TUMORS; CRANIOSPINAL RADIATION-THERAPY; PEDIATRIC-ONCOLOGY SIOP; POSTERIOR-FOSSA TUMORS; THAN; YEARS; CHILDHOOD MEDULLOBLASTOMA; ADJUVANT CHEMOTHERAPY; INTERNATIONAL-SOCIETY; POSTOPERATIVE CHEMOTHERAPY;
D O I
10.1016/j.clon.2012.09.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Medulloblastomas are primary malignant embryonal tumours of the central nervous system. They are the most common childhood central nervous system tumour, but are rare in the adult population. They arise infratentorially in the cerebellum or fourth ventricle and hence the most common presenting symptoms are those associated with raised intracranial pressure. Several histological subtypes have been described, although the classical and desmoplastic subtypes account for the majority. Recent advances in molecular biology and cytogenetics have led to an improved understanding of the genetic abnormalities and alterations in cell signalling pathways associated with medulloblastomas, including how these relate to patient outcome. The Modified Chang Staging System is still in use, but a number of other factors, including age, completeness of resection, histological subtype and genetic markers now contribute to treatment decisions and prognostication. Patients are currently classified as being either standard or high risk in order to stratify treatment. There has been an improvement in survival of all groups over the past 20 years. A multimodality approach is the cornerstone of treatment and recent trials have concentrated on ascertaining the most efficacious treatment combinations and timings for each patient group. Advances in surgical techniques have allowed a greater attainment of the two primary surgical goals: restoring normal cerebrospinal fluid (CSF) flow and maximal tumour resection. Radiotherapy to the craniospinal axis with a boost to the posterior fossa has been standard practice, but improvement in radiotherapy techniques and quality control has enabled optimisation of the trade-off between tumour control and normal tissue late toxicities. Combination chemotherapy is usually given adjuvantly, although it may be used to delay or avoid the use of radiotherapy in infants. In the future, the treatment of medulloblastoma will probably become increasingly individualised, based on patient-specific genetic features. Attention will be focussed not only on improving survival, but also on maintaining quality of life. (c) 2012 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.
引用
收藏
页码:36 / 45
页数:10
相关论文
共 72 条
  • [1] A PHASE II STUDY OF PRERADIOTHERAPY CHEMOTHERAPY FOLLOWED BY HYPERFRACTIONATED RADIOTHERAPY FOR NEWLY DIAGNOSED HIGH-RISK MEDULLOBLASTOMA/PRIMITIVE NEUROECTODERMAL TUMOR: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (CCG 9931)
    Allen, Jeffrey
    Donahue, Bernadine
    Mehta, Minesh
    Miller, Douglas C.
    Rorke, Lucy B.
    Jakacki, Regina
    Robertson, Patricia
    Sposto, Richard
    Holmes, Emi
    Vezina, Gilbert
    Muraszko, Karin
    Puccetti, Diane
    Prados, Michael
    Chan, Ka-Wah
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 74 (04): : 1006 - 1011
  • [2] Childhood medulloblastoma in northwest England 1954 to 1997: incidence and survival
    Alston, RD
    Newton, R
    Kelsey, A
    Newbould, MJ
    Birch, JM
    Lawson, B
    McNally, RJQ
    [J]. DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2003, 45 (05) : 308 - 314
  • [3] PROSPECTIVE RANDOMIZED TRIAL OF CHEMOTHERAPY GIVEN BEFORE RADIOTHERAPY IN CHILDHOOD MEDULLOBLASTOMA - INTERNATIONAL-SOCIETY-OF-PEDIATRIC-ONCOLOGY (SIOP) AND THE (GERMAN)-SOCIETY-OF-PEDIATRIC-ONCOLOGY (GPO) - SIOP-II
    BAILEY, CC
    GNEKOW, A
    WELLEK, S
    JONES, M
    ROUND, C
    BROWN, J
    PHILLIPS, A
    NEIDHARDT, MK
    [J]. MEDICAL AND PEDIATRIC ONCOLOGY, 1995, 25 (03): : 166 - 178
  • [4] Medulloblastoma cerebelli - A common type of midcerebellar glioma of childhood
    Bailey, P
    Cushing, H
    [J]. ARCHIVES OF NEUROLOGY AND PSYCHIATRY, 1925, 14 (02): : 192 - 224
  • [5] The Management of Hydrocephalus in Children with Posterior Fossa Tumours: The Role of Pre-Resectional Endoscopic Third Ventriculostomy
    Bhatia, Robin
    Tahir, Mohammed
    Chandler, Christopher L.
    [J]. PEDIATRIC NEUROSURGERY, 2009, 45 (03) : 186 - 191
  • [6] A comparison of conventional, conformal and intensity-modulated coplanar radiotherapy plans for posterior fossa treatment
    Breen, SL
    Kehagioglou, P
    Usher, C
    Plowman, PN
    [J]. BRITISH JOURNAL OF RADIOLOGY, 2004, 77 (921) : 768 - 774
  • [7] Bühren J, 2000, J NEUROPATH EXP NEUR, V59, P229
  • [8] Impact of targeting deviations on outcome in medulloblastoma: Study of the French Society of Pediatric Oncology (SFOP)
    Carrie, C
    Hoffstetter, S
    Gomez, F
    Moncho, V
    Doz, F
    Alapetite, C
    Murraciole, X
    Maire, JP
    Benhassel, M
    Chapet, S
    Quetin, P
    Kolodie, H
    Lagrange, JL
    Cuillere, JC
    Habrand, JL
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 45 (02): : 435 - 439
  • [9] AN OPERATIVE STAGING SYSTEM AND A MEGAVOLTAGE RADIOTHERAPEUTIC TECHNIC FOR CEREBELLAR MEDULLOBLASTOMAS
    CHANG, CH
    HOUSEPIAN, EM
    HERBERT, C
    [J]. RADIOLOGY, 1969, 93 (06) : 1351 - +
  • [10] The gene for the naevoid basal cell carcinoma syndrome acts as a tumour-suppressor gene in medulloblastoma
    Cowan, R
    Hoban, P
    Kelsey, A
    Birch, JM
    Gattamaneni, R
    Evans, DGR
    [J]. BRITISH JOURNAL OF CANCER, 1997, 76 (02) : 141 - 145